Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics is attractive because deramiocel has advancing Phase 3 data that showed a 4.55% treatment difference in PUL2.0 at 12 months and supportive open-label extension evidence, while the FDA has already accepted the major BLA amendment and extended the PDUFA date to 11/22. The investment case also benefits from a potentially narrower upper-limb indication, which panelists appeared more open to, and a possible Rare Pediatric Disease Priority Review Voucher if approved. Financially, the company ended 2Q:26 with $238 million in cash, and the setup remains asymmetric given that shares are still trading against high skepticism despite being up 117% off the post-AdComm 52-wk low.

Capricor Therapeutics is a highly speculative biotech because its value depends almost entirely on Deramiocel, an allogeneic cell therapy still in Phase 3, while the rest of the pipeline remains early stage and may take a long time to mature. Despite HOPE-2 showing statistically significant improvements in 20 patients over 12 months and the OLE suggesting continued on-drug benefit, the recent negative FDA AdComm and uncertainty over whether the dataset is sufficient for filing create a meaningful regulatory overhang. The stock also faces financing and legal risk, since a delay could jeopardize the expected >$230M non-dilutive cash infusion and force costly equity or debt, while litigation with its U.S. commercialization partner could disrupt launch economics.